WO2000037500A1 - Three dimensional structure of a sterile alpha motif domain - Google Patents
Three dimensional structure of a sterile alpha motif domain Download PDFInfo
- Publication number
- WO2000037500A1 WO2000037500A1 PCT/CA1999/001209 CA9901209W WO0037500A1 WO 2000037500 A1 WO2000037500 A1 WO 2000037500A1 CA 9901209 W CA9901209 W CA 9901209W WO 0037500 A1 WO0037500 A1 WO 0037500A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- atom
- sam
- sam domain
- arg
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- TITLE Three Dimensional Structure of a Sterile Alpha Motif Domain FIELD OF THE INVENTION
- the invention relates to the three dimensional structure of a sterile alpha motif (Sam) domain.
- the atomic coordinates that define the structure and any compounds bound to the structure enable the determination of homologues, the three dimensional structures of polypeptides with unknown structure, and the identification of modulators of a SAM domain.
- Eph family of receptor tyrosine kinases have been implicated in the control of axon guidance [Henkemeyer, 1996; Orioli, 1996], cell migration [Krull, 1997], patterning of the nervous system [Xu, 1996] and angiogenesis [Wang, 1998], and are activated by clustering into dimers or tetramers [Stein, 1998].
- the cell-surface ligands for Eph receptors ephrins
- Factors that influence receptor aggregation include the pre-clustering of ephrins [Davis, 1994], the homotypic interaction between the extracellular domains of two receptor chains [Lackmann, 1998], and the binding of PDZ domain containing proteins to the receptor's C-terminus [Hock, 1998].
- SAM Sterile Alpha Motif
- the SAM domain was identified as a conserved sequence present in a small set of yeast sexual differentiation proteins referred to as the Sterile Alpha Mating factors [Ponting, 1995; Schultz, 1997]. In ETS family transcription factors this sequence has also been termed the Pointed domain [Klambt, 1993]. The domain is found in a variety of proteins, many of which contain catalytic domains or recognized protein interaction domains. SAM domains are almost always located at a protein's N- or C-terminus. A highly conserved SAM domain is located in the cytoplasmic region of Eph receptors (approx.
- the SAM domain can function as a protein interaction module through an ability to homo- and hetero-dimerize with other SAM domains [Jousset, 1997; Peterson, 1997; Tu, 1997; Kyba, 1998]. This dimerizing property elicits oncogenic activation of chimeric proteins arising from translocation of the SAM domain of TEL to coding regions of the ⁇ PDGF receptor [Golub, 1994); Abl [Golub, 1996], and JAK2 protein kinases [Lacronique, 1997] or the AML1 transcription factor [Golub, 1995].
- the present invention relates to the three-dimensional structure of one or more SAM domains.
- the three-dimensional structures may be complexed with one or more compounds.
- the defined boundaries and properties of the structures and any of the compounds bound to it are pertinent to methods for determining the three-dimensional structures of polypeptides with unknown structure, and to methods that identify modulators of SAM domain function.
- modulators are potentially useful as therapeutics for diseases, including (but not limited to) cell proliferative diseases, such as cancer, angiogenesis, atherosclerosis, and arthritis, and diseases associated with the nervous system.
- the present invention relates to a crystalline form of a polypeptide corresponding to one or more SAM domains, preferably one or more SAM domains of an Eph receptor, preferably of EphA.
- the crystalline form may comprise one or more heavy metal atoms, or at least one compound.
- the invention also relates to a method of forming a crystalline form of the invention comprising
- step (b) incubating the mixture obtained in step (a) over the reservoir solution in a closed container under conditions suitable for crystallization.
- the invention also features a method of determining three dimensional structures of polypeptides with unknown structure comprising the step of applying the structural atomic coordinates of a crystalline form of one or more SAM domains of the invention.
- Methods are also provided for identifying a potential modulator of a SAM domain function preferably a SAM domain of an Eph receptor function by docking a computer representation of a structure of a compound with a computer representation of a structure of one or more SAM domains of the invention preferably a SAM domain of an Eph receptor that is defined by the atomic structural coordinates described herein.
- the method comprises the following steps:
- the method comprises the following steps: (a) selecting a computer representation of a compound complexed with a selected site on a SAM domain, preferably a SAM domain of an Eph receptor; and
- the invention also features a potential modulator of a function of a SAM domain preferably a SAM domain of an Eph receptor identified by the methods of the invention, and a method of treating a disease associated with a SAM domain preferably a SAM domain of an Eph receptor with inappropriate activity in a cellular organism, comprising:
- Figure 1A shows a sequence alignment of SAM domains from selected proteins (SEQ. ID. NOS. 1 to 21);
- Figure IB shows a selection of multi-domain proteins containing SAM domain (S);
- Figure 2A is a ribbons depiction of the SAM homo-dimer viewed down the twofold symmetry axis;
- Figure 2B is a ribbons depiction of the SAM homo-dimer viewed perpendicular to the symmetry axis;
- Figure 2C is a ribbons stereo view highlighting the dimer interface region
- Figure 3 A is a molecular surface and worm representation of the SAM homodimer
- Figure 3B is a molecular surface and worm representation of the SAM homodimer.
- Figure 4 is a gel filtration elution profile of wild type and single or double site mutants of the EphA4 receptor SAM domain.
- amino acid residues are the standard 3-letter and/or 1 -letter codes used in the art to refer to one of the 20 common L-amino acids.
- nucleic acids are the standard codes used in the art.
- crystalline form in the context of the invention, is a crystal formed from an aqueous solution comprising a purified polypeptide comprising one or more SAM domains, preferably a SAM domain of an Eph receptor.
- a crystalline form of a SAM domain is characterized as being capable of diffracting x-rays in a pattern defined by one of the crystal forms depicted in Blundel et al 1976, Protein Crystallography, Academic Press.
- a crystalline form may include a crystal structure in association with one or more heavy-metal atoms i.e. a derivative crystal, or a crystal structure in association with one or more compounds i.e. a co-crystal.
- association refers to a condition of proximity between a chemical entity or compound or portions or fragments thereof, and a SAM domain or portions or fragments thereof.
- the association may be non-covalent i.e. where the juxtaposition is energetically favored by for example, hydrogen-bonding, van der Waals, or electrostatic or hydrophobic ineractions, or it may be covalent.
- the term “heavy-metal atoms” refers to an atom that is a transition element, a lanthanide metal, or an actinide metal.
- Lanthanide metals include elements with atomic numbers between 57 and 71, inclusive.
- Actinide metals include elements with atomic numbers between 89 and 103, inclusive.
- Eph receptor refers to a subfamily of closely related transmembrane receptor tyrosine kinases related to Eph, a receptor named for its expression in an erythropoietin-producing human hepatocellular carcinomas cell line.
- the receptors contain cell adhesion-like domains on their extracellular surface.
- the Eph subfamily receptor tyrosine kinases are more specifically characterised as encoding a structurally related cysteine rich extracellular domain containing a single immunoglobulin (Ig)-like loop near the N-terminus and two fibronectin III (FN HI) repeats adjacent to the plasma membrane.
- the Eph receptors are divided into two groups based on the relatedness of their extracellular domain sequences.
- EphA also corresponds to the ability of the receptors to bind preferentially to the ephrin-A or ephrin-B proteins.
- EphA also known as Eph and Esk
- EphA2 also known as Eck, Myk2, Sek2
- EphA3 also known as Cek4, Mek4, Hek, Tyro4, Hek4
- EphA4 also known as Sek, Sekl, Cek8, Hek8, Tyrol
- EphA5 also known as Ehkl, Bsk, Cek7, Hek7, and Rek7
- EphA6 Ephk2, and Hekl2
- EphA7 also known as Mdkl, Hekl 1, Ehk3, Ebk, Cekl 1
- EphA8 also known as Eek, Hek3.
- Eph B The group that includes receptors interacting preferentially with ephrin B proteins is called Eph B and includes EphBl (also known as Elk, Cek6, Net, Hek6), EphB2 (also known as Cek5, Nuk, Erk, Qek5, Tyro5, Sek3, hek5, Drt), EphB3 (also known as CeklO, Hek2, Mdk5, Tyro6, and Sek4), EphB4 (also known as Htk, Mykl, Tyrol 1, Mdk2), EphB5 (also known as Cek9, Hek9), and EphB6 (also known as Mep).
- EphBl also known as Elk, Cek6, Net, Hek6
- EphB2 also known as Cek5, Nuk, Erk, Qek5, Tyro5, Sek3, hek5, Drt
- EphB3 also known as CeklO, Hek2, Mdk5, Tyro6, and Sek4
- EphB4 also known
- Ephrin refers to a class of ligands which are anchored to the cell membrane through a transmembrane domain, and bind to the extracellular domain of an Eph receptor, facilitating dimerization and autophosphorylation of the receptor and autophosphorylation of the ligand.
- the ephrins which are targeted in the methods of the invention are those that bind to and activate (i.e. phosphorylate) an EphA or an EphB receptor, preferably an EphA receptor.
- the ephrin-A ligands are ephrin-A (also known as B61, LERKl, EFL-1), ephrin- A2 (also known as LERK6, Elfl, mCek7-L, cElfl), ephrin-A3 (also known as LERK3, Ehkl-L, and EFL-2), ephrin-A4 (also known as LERK4, EFL-4, mLERK4), ephrin-A5 (AL1, LERK7, EFL-5, mALl, [rLERK.7], RAGS), and the ephrin-B ligands (transmembrane ligands) are ephrin-B 1 (also known as LEKR2, ELK-L, EFL-3, Cek5-L, Stral, [LERK2]), ephrin-B2 (also known as LEKR2, ELK-
- SAM domain refers to a region known as the Sterile Alpha Motif (SAM) domain within the cytoplasmic regions of all Eph receptors ( Figure IB), and in other proteins such as TEL [Jousset, 1997], members of the polycomb group of transcriptional repressors (RAE28, Scm and ph) [Peterson, 1997], the protein kinase Byr2p [Tu, 1997], the and ⁇ isoforms of the liprin scaffolding proteins [Serra-Pages, 1998], and tankyrase (Smith, S. et al, Science 282: 1484-1487, 1998, Acession AF082556).
- SAM Sterile Alpha Motif
- the SAM domain was identified as a conserved sequence present in a small set of yeast sexual differentiation proteins referred to as the Sterile Alpha Mating factors [Ponting, 1995; Schultz, 1997]. In ETS family transcription factors this sequence has also been termed the Pointed domain [Klambt, 1993]. Extensive database searching and sequence alignment analysis ( Figure 1A) reveals that this domain is found in a variety of proteins, many of which contain catalytic domains or recognized protein interaction domains ( Figure IB). SAM domains are almost always located at a protein's N- or C-terminus.
- SAM domain is located in the cytoplasmic region of Eph receptors (approximately 50 % identity over 14 family members), C-terminal to the catalytic domain and followed by only 5 residues that form a potential PDZ domain binding site [Hock, 1998].
- the term also includes amino acid sequences having substantial sequence identity to a SAM domain, a mutant, or a subunit of a SAM domain.
- the SAM domain is an "Eph SAM domain” i.e. a SAM domain of an Eph receptor.
- SAM domain structure or "SAM domain three dimensional structure” refers to the three dimensional structure of a purified polypeptide comprising one or more SAM domains, preferably a crystalline form.
- the term " substantial sequence identity” means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap, share at least 80 percent sequence identity, preferably at least 90 percent sequence identity, more preferably at least 95 percent sequence identity or more.
- residue positions which are not identical differ by conservative amino acid substitutions.
- substitution of amino acids having similar chemical properties such as charge or polarity are not likely to effect the properties of a protein. Examples include glutamine for asparagine or glutamic acid for aspartic acid.
- the term "mutant" refers to a polypeptide that is obtained by replacing at least one amino acid residue in a native SAM domain with a different amino acid residue. Mutation can be accomplished by adding and/or deleting amino acid residues within the native SAM domain. A mutant may or may not be functional.
- function refers to the ability of a modulator to enhance or inhibit the association between a SAM domain and a compound.
- atomic structural coordinates refers to a data set that defines the three dimensional structure of a molecule or molecules (e.g. unit cell axial lengths, space group). Structural coordinates can be slightly modified and still render nearly identical three dimensional structures. A measure of a unique set of structural coordinates is the root-mean-square deviation of the resulting structure. Structural coordinates that render three dimensional structures that deviate from one another by a root-mean-square deviation of less than 1.5 A may be viewed by a person of ordinary skill in the art as identical. Structural coordinates for a SAM domain are in Table 2.
- unit cell refers to the smallest and simplest volume element (i.e. parallelpiped- shaped block) of a crystal that is completely representative of the unit of pattern of the crystal.
- space group refers to the symmetry of a unit cell.
- capital letter indicates the lattice type and the other symbols represent symmetry operations that can be carried out on the unit cell without changing its appearance.
- a purified polypeptide does not require absolute purity such as a homogenous preparation rather it represents an indication that the sequence is relatively purer than in the natural environment.
- a purified polypeptide is substantially free of other proteins, lipids, carbohydrates, or other materials with which it is naturally associated, preferably at a functionally significant level for example at least 85% pure, more preferably at least 95% pure, most preferably at least 99% pure.
- a skilled artisan can purify a polypeptide comprising a SAM domain using standard techniques for protein purification.
- a substantially pure polypeptide comprising a Sam domain will yield a single major band on a non-reducing polyacrylamide gel.
- the purity of the SAM domain polypeptide can also be determined by amino-terminal amino acid sequence analysis.
- the present invention provides a purified SAM domain three dimensional structure.
- the structure is a crystalline form.
- a SAM domain structure may comprise one or more SAM domains in a unit cell, preferably two, three or four SAM domains.
- a crystalline form includes native crystals, derivative crystals, and co-crystals.
- the native crystals generally comprise substantially pure polypeptides comprising one or more SAM domains in crystalline form. It is understood that the crystalline form is not limited to naturally occurring or native SAM domains but includes mutants of native SAM domains obtained by replacing at least one amino acid residue in a native SAM domain with a different amino acid residue or by adding or deleting amino acid residues within the native polypeptide, and having substantially the same three dimensional structure as the native SAM domain from which the mutant is derived i.e.
- mutants contemplated herein need not exhibit SAM domain activity.
- the derivative crystals of the invention generally comprise a crystalline SAM domain in covalent association with one or more heavy metal atoms.
- the SAM domain may correspond to a native or mutated SAM domain.
- Heavy metal atoms useful for providing derivative crystals include by way of example, and not limitation gold, mercury, etc.
- the invention features a crystalline form of a SAM domain in association with one or more compounds.
- the association may be covalent or non-covalent. These types of crystalline forms are referred to herein as co-crystals.
- the compound may be any organic molecule, and it may modulate the function of a SAM domain by for example inhibiting or enhancing its function, or it may be an analogue of a SAM domain. It is preferred that the geometry of the compound and the interactions formed between the compound and the SAM domain provide high affinity binding between the two molecules. High affinity binding is preferably governed by a dissociation equilibrium constant on the order of 10 '6 or less.
- the invention also features a method for creating the crystalline SAM domain structures described herein.
- the method may utilize a polypeptide comprising a SAM domain described herein to form a crystal.
- a polypeptide used in the method may be chemically synthesized in whole or in part using techniques that are well-known in the art.
- methods are well known to the skilled artisan to construct expression vectors containing the native or mutated SAM domain coding sequence and appropriate transcriptional/translational control signals. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo recombination/genetic recombination. See for example the techniques described in Sambrook et al. (Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press (1989)), and other laboratory textbooks.
- Crystals are grown from an aqueous solution containing the purified and concentrated SAM domain polypeptide by a variety of conventional processes. These processes include batch, liquid, bridge, dialysis, vapor diffusion, and hanging drop methods. (See for example, McPherson, 1982 John Wiley, New York; McPherson, 1990, Eur. J. Biochem. 189: 1-23; Webber. 1991, Adv. Protein Chem. 41 :1-36).
- the native crystals of the invention are grown by adding precipitants to the concentrated solution of the SAM domain polypeptide. The precipitants are added at a concentration just below that necessary to precipitate the protein. Water is removed by controlled evaporation to produce precipitating conditions, which are maintained until crystal growth ceases.
- the method generally comprises the steps of (a) mixing a volume of polypeptide solution with a reservoir solution; and
- step (b) incubating the mixture obtained in step (a) over the reservoir solution in a closed container, under conditions suitable for crystallization.
- crystals of the invention it has been found that hanging drops containing about 1 ⁇ l of SAM domain polypeptide (50-150 mg/ml, preferably 100 mg/ml, in 5-2-mM, preferably 7mM Hepes pH 5.5 to 9, preferably 7.5) and equal volumes of reservoir buffer (50-150 mM, preferably lOOmM cacodylate pH 5.5 to 7.5, preferably 6.5; 5-10% preferably 7% (w/v) PEG 8000; and 10-30%, preferably 20% (v/v) ethylene glycol) suspended overnight at room temperature provide crystals suitable for high resolution X-ray structure determination.
- reservoir buffer 50-150 mM, preferably lOOmM cacodylate pH 5.5 to 7.5, preferably 6.5; 5-10% preferably 7% (w/v) PEG 8000; and 10-30%, preferably 20% (v/v) ethylene glycol
- Derivative crystals of the invention can be obtained by soaking native crystals in a solution containing salts of heavy metal atoms.
- Co-crystals of the invention can be obtained by soaking a native crystal in a solution containing a compound that binds the SAM domain, or they can be obtained by co-crystallizing the SAM domain polypeptide in the presence of one or more compounds that bind to the SAM domain.
- the crystal can be placed in a glass capillary tube and mounted onto a holding device connected to an X-ray generator and an X-ray detection device. Collection of X-ray diffraction patterns are well documented by those skilled in the art (See for example, Ducruix and Geige, 1992, IRL Press, Oxford, England). A beam of X-rays enter the crystal and diffract from the crystal. An X-ray detection device can be utilized to record the diffraction patterns emanating from the crystal. Suitable devices include the Marr 345 imaging plate detector system with an RU200 rotating anode generator.
- the unit cell dimensions and orientation in the crystal can be determined from the spacing between the diffraction emissions as well as the patterns made from the emissions. The symmetry of the unit cell in the crystal is also determined.
- Each diffraction pattern emission is characterized as a vector and the data collected at this stage determines the amplitude of each vector.
- the phases of the vectors may be determined by the isomorphous replacement method where heavy atoms soaked into the crystal are used as reference points in the X-ray analysis (see for example, Otwinowski, 1991, Daresbury, United Kingdom, 80-86).
- the phases of the vectors may also be determined by molecular replacement (see for example, Naraza, 1994, Proteins 11:281-296).
- the amplitudes and phases of vectors from the crystalline form of an Eph SAM domain, preferably an EphA4 SAM domain, determined in accordance with these methods can be used to analyze other crystalline SAM domains.
- the unit cell dimensions and symmetry, and vector amplitude and phase information can be used in a Fourier transform function to calculate the electron density in the unit cell i.e. to generate an experimental electron density map. This may be accomplished used the PHASES package (Furey,
- Amino acid sequence structures are fit to the experimental electron density map (ie. model building) using computer programs (e.g. Jones, TA. et al, Acta Crystallogr A47, 100-119, 1991) to calculate a theoretical electron density map.
- the theoretical and experimental electron density maps can be compared and the agreement between the maps can be described by a parameter referred to as R-factor.
- R-factor can be minimized by using computer programs that refine the theoretical electron density map.
- the XPLOR program developed by Brunger (1992, Nature 355:472-475) can be used for model refinement.
- a three dimensional structure of the molecule or complex may be described by atoms that fit the theoretical electron density characterized by a minimum R value. Files can be created for the structure that defines each atom by coordinates in three dimensions. Identification of Homologues
- the structure coordinates of a SAM domain structure described herein can be used as a model for determining the three dimensional structures of additional native or mutated SAM domains with unknown structure, as well as the structures of co-crystals of SAM domains with compounds such as modulators (e.g. agonists or antagonists).
- the structure coordinates and models of a SAM domain three dimensional structure can also be used to determine solution-based structures of native or mutant SAM domains.
- Three dimensional structure may be determined by applying the structural coordinates of a SAM domain structure to other data such as an amino acid sequence, X-ray crystallographic diffraction data, or nuclear magnetic resonance (NMR) data. Homology modeling, molecular replacement, and nuclear magnetic resonance methods using these other data sets are described below.
- Homology modeling also known as comparative modeling or knowledge-based modeling
- the method utilizes a computer representation of the three dimensional structure of a SAM domain, preferably the EphA SAM domain, more preferably the EphA4 SAM domain, or a complex of same, a computer representation of the amino acid sequence of a polypeptide with an unknown structure, and standard computer representations of the structures of amino acids.
- the method in particular comprises the steps of; (a) identifying structurally conserved and variable regions in the known structure; (b) aligning the amino acid sequences of the known structure and unknown structure (c) generating coordinates of main chain atoms and side chain atoms in structurally conserved and variable regions of the unknown structure based on the coordinates of the known structure thereby obtaining a homology model; and (d) refining the homology model to obtain a three dimensional structure for the unknown structure.
- This method is well known to those skilled in the art (Greer, 1985, Sceince 228, 1055; Bundell et al 1988, Eur. J. Biochem.
- step (a) of the homology modeling method the known SAM domain structure (e.g. structure of the EphA4 SAM domain) is examined to identify the structurally conserved regions (SCRs) from which an average structure, or framework, can be constructed for these regions of the protein.
- SAM domain structure e.g. structure of the EphA4 SAM domain
- VRs Variable regions
- SCRs generally correspond to the elements of secondary structure, such as alpha-helices (the four ⁇ -helices in the EphA4 SAM domain) and beta-sheets, and to ligand- and substrate-binding sites.
- the VRs usually lie on the surface of the proteins and form the loops where the main chain turns.
- Sequence alignments generally are based on the dynamic programming algorithm of Needleman and Wunsch [J. Mol. Biol. 48: 442-453, 1970]. Current methods include FASTA, Smith- Waterman, and BLASTP, with the BLASTP method differing from the other two in not allowing gaps. Scoring of alignments typically involves construction of a 20x20 matrix in which identical amino acids and those of similar character (i.e., conservative substitutions) may be scored higher than those of different character. Substitution schemes which may be used to score alignments include the scoring matrices PAM (Dayhoff et al., Meth. Enzymol. 91 : 524-545, 1983), and BLOSUM (Henikoff and Henikoff, Proc.
- PAM Dayhoff et al., Meth. Enzymol. 91 : 524-545, 1983
- BLOSUM Henikoff and Henikoff, Proc.
- Alignment based solely on sequence may be used, though other structural features also may be taken into account.
- multiple sequence alignment algorithms are available that may be used when aligning a sequence of the unknown with the known structures.
- Four scoring systems i.e. sequence homology, secondary structure homology, residue accessibility homology, CA-CA distance homology
- sequence homology i.e. sequence homology, secondary structure homology, residue accessibility homology, CA-CA distance homology
- CA-CA distance homology i.e. sequence homology, secondary structure homology, residue accessibility homology, CA-CA distance homology
- main chain atoms and side chain atoms both in SCRs and VRs need to be modeled.
- a variety of approaches known to those skilled in the art may be used to assign coordinates to the unknown. In particular, the coordinates of the main chain atoms of SCRs will be transferred to the unknown structure.
- VRs correspond most often to the loops on the surface of the polypeptide and if a loop in the known structure is a good model for the unknown, then the main chain coordinates of the known structure may be copied. Side chain coordinates of SCRs and VRs are copied if the residue type in the unknown is identical to or very similar to that in the known structure. For other side chain coordinates, a side chain rotamer library may be used to define the side chain coordinates. When a good model for a loop cannot be found fragment databases may be searched for loops in other proteins that may provide a suitable model for - l i the unknown. If desired, the loop may then be subjected to conformational searching to identify low energy conformers if desired.
- Molecular replacement involves applying X-ray diffraction data of a known structure to the incomplete X-ray crystallographic data set of a polypeptide of unknown structure.
- the method can be used to define the phases describing the X-ray diffraction data of a polypeptide of unknown structure when only the amplitudes are known.
- Commonly used computer software packages for molecular replacement are X-PLOR (Brunger 1992, Nature 355: 472-475), AMoRE (Navaza, 1994, Acta Crystallogr. A50:157-163), the CCP4 package (Collaborative Computational Project, Number 4, "The CCP4 Suite: Programs for Protein Crystallography", Acta Cryst., Vol. D50, pp.
- the objective of molecular replacement is to align positions of atoms in the unit cell by matching electron diffraction data from two crystals.
- Molecular replacement computer programs generally involve the following steps: (1) determining the number of molecules in the unit cell and defining the angles between them; (2) rotating the diffraction data to define the orientation of the molecules in the unit cell; (3) translating the electron density in three dimensions to correctly position the molecules in the unit cell; (4) determining the amplitudes and phases of the X-ray diffraction data and calculating an R-factor calculated from the reference data set and from the new data wherein an R-factor between 30-50% indicates that the orientations of the atoms in the unit cell have been reasonably determined by the method; and (5) optionally decreasing the R-factor to about 20% by refining the new electron density map using iterative refinement techniques known to those skilled in the art.
- a method for determining three dimensional structures of polypeptides with unknown structure by applying the structural coordinates of a SAM domain structure to an incomplete X-ray crystallographic data set for a polypeptide of unknown structure, and determining a low energy conformation of the resulting structure.
- the structural coordinates of a SAM domain structure may be applied to nuclear magnetic resonance (NMR) data to determine the three dimensional structures of polypeptides.
- NMR nuclear magnetic resonance
- While the secondary structure of a polypeptide may often be determined by NMR data, the spatial connections between individual pieces of secondary structure are not as readily determined.
- the structural coordinates of a polypeptide defined by X-ray crystallography can guide the NMR spectroscopist to an understanding of the spatial interactions between secondary structural elements in a polypeptide of related structure. Information on spatial interactions between secondary structural elements can greatly simplify Nuclear Overhauser Effect (NOE) data from two-dimensional NMR experiments.
- NOE Nuclear Overhauser Effect
- applying the structural coordinates after the determination of secondary structure by NMR techniques simplifies the assignment of NOE's relating to particular amino acids in the polypeptide sequence and does not greatly bias the NMR analysis of polypeptide structure.
- the invention relates to a method of determining three dimensional structures of polypeptides with unknown structures by applying the structural coordinates of a SAM domain structure to nuclear magnetic resonance (NMR) data of the unknown structure.
- This method comprises the steps of: (a) determining the secondary structure of an unknown structure using NMR data; and (b) simplifying the assignment of through-space interactions of amino acids.
- through-space interactions defines the orientation of the secondary structural elements in the three dimensional structure and the distances between amino acids from different portions of the amino acid sequence.
- the term "assignment” defines a method of analyzing NMR data and identifying which amino acids give rise to signals in the NMR spectrum. Identification of Potential Modulators of SAM Domains
- Modulators of a SAM domain may be designed and identified that may modify the inappropriate activity of a SAM domain involved in a clinical disorder.
- the rational design and identification of modulators of SAM domains can be accomplished by utilizing the atomic structural coordinates that define a SAM domain's three dimensional structure.
- Modulators may include substances that bind to or mimic the residues of a SAM domain that are required for dimerization of SAM domains.
- a substance that binds to or mimics the interface residues of an EphA SAM domain e.g. Val 913, Val 914, Met 972, Met 976, Met 979, Val 944, and Leu 940
- the proximal residues of an EphA SAM domain e.g. He 959 to Lys
- Structure-based modulator design identification methods are powerful techniques that can involve searches of computer databases containing a variety of potential modulators and chemical functional groups.
- SAM domain three dimensional structure described herein, and the three dimensional structures of other polypeptides determined by the homology modeling, molecular replacement, and NMR techniques described herein can also be applied to modulator design and identification methods.
- Modulators of SAM domains may be identified by docking the computer representation of compounds from a database of molecules. Databases which may be used include ACD (Molecular Designs Limited), NCI (National Cancer Institute), CCDC (Cambridge Crystallographic Data Center), CAST (Chemical Abstract Service), Derwent (Derwent Information Limited), Maybridge (Maybridge Chemical Company Ltd), Aldrich (Aldrich Chemical Company), DOCK (University of California in San Francisco), and the Directory of Natural Products (Chapman & Hall).
- Computer programs such as CONCORD (Tripos Associates) or DB-Converter (Molecular Simulations Limited) can be used to convert a data set represented in two dimensions to one represented in three dimensions. Generally, the computer programs comprise the following steps:
- (d) linking the fragments found in (c) to the compound and evaluating the new modified compound.
- “Docking” refers to a process of placing a compound in close proximity with an active site of a polypeptide (e.g.. an Eph SAM domain), or a process of finding low energy conformations of a compound/polypeptide complex (e.g. compound Eph SAM domain).
- CAVEAT Bartlett et al., 1989, in "Chemical and Biological Problems in Molecular Recognition", Roberts, S.M. Ley, S.V.; Campbell, N.M. eds; Royal Society of Chemistry: Cambridge, pp 182-196
- FLOG iller et al., 1994, J. Comp. Aided Molec. Design 8:153
- PRO Modulator Clark et al., 1995 J. Comp. Aided Molec. Design 9:13
- MCSS Meranker and Karplus, 1991, Proteins: Structure, Fuction, and Genetics 8:195
- GRID Goodford, 1985, J. Med.
- a method for identifying potential modulators of SAM domain function.
- the method utilizes the structural coordinates of a SAM domain three dimensional structure.
- the method comprises the steps of (a) removing a computer representation of a SAM domain structure, preferably an Eph SAM domain structure, more preferably an EphA4 SAM domain structure, and docking a computer representation of a compound from a computer data base with a computer representation of the active site of the SAM domain; (b) determining a conformation of the complex with a favourable geometric fit or favorable complementary interactions; and (c) identifying compounds that best fit the SAM domain active-site as potential modulators of SAM domain function.
- the initial SAM domain structure may or may not have compounds bound to it.
- a favourable geometric fit occurs when the surface areas of a compound in a compound-SAM domain complex is in close proximity with the surface area of the active-site of the SAM domain without forming unfavorable interactions.
- a favourable complementary interaction occurs where a compound in a compound-SAM domain complex interacts by hydrophobic, aromatic, ionic, or hydrogen donating and accepting forces, with the active-site of a SAM domain without forming unfavorable interactions. Unfavourable interactions may be steric hindrance between atoms in the compound and atoms in the SAM active-site.
- potential modulators are identified utilizing a three dimensional structure of a SAM domain with or without compounds bound to it.
- the method comprises the steps of (a) modifying a computer representation of a SAM domain (e.g. an Eph SAM domain) having one or more compounds bound to it, where the computer representations of the compound or compounds and SAM domain are defined by atomic structural coordinates; (b) determining a conformation of the complex with a favorable geometric fit and favorable complementary interactions; and (c) identifying the compounds that best fit the SAM active site as potential modulators.
- a computer representation may be modified by deleting or adding a chemical group or groups. Computer representations of the chemical groups can be selected from a computer database.
- modulators can be modified within the computer representation of a SAM domain active-site. This technique is described in detail in Molecular Simulations User Manual, 1995 in LUDI.
- the computer representation of a modulator may be modified by deleting a chemical group or groups, or by adding a chemical group or groups. After each modification to a compound, the atoms of the modified compound and active-site can be shifted in conformation and the distance between the modulator and the active site atoms may be scored on the basis of geometric fit and favourable complementary interactions between the molecules. Compounds with favourable scores are potential modulators.
- Compounds designed by modulator building or modulator searching computer programs may be screened to identify potential modulators.
- Examples of such computer programs include programs in the Molecular Simulations Package (Catalyst), ISIS/HOST, ISIS/BASE, and ISIS/DRAW (Molecular Designs Limited), and UNITY (Tripos Associates).
- a building program may be used to replace computer representations of chemical groups in a compound complexed with a SAM domain with groups from a computer data base.
- a searching program may be used to search computer representations of compounds from a computer database that have similar three dimensional structures and similar chemical groups as a compound that binds to a SAM domain.
- the programs may be operated on the structure of the active-site of the three dimensional structure of an Eph SAM domain, preferably an EphA4 SAM domain.
- a typical program may comprise the following steps:
- mapping chemical features of the compound such as by hydrogen bond donors or acceptors, hydrophobic/lipophilic sites, positively ionizable sites, or negatively ionizable sites;
- a method of identifying potential modulators of a SAM domain preferably an Eph SAM domain, more preferably an EphA SAM domain, is provided using the three dimensional conformation of the SAM domain in various modulator construction or modulator searching computer programs on compounds complexed with the SAM domain.
- the method comprises the steps of (a) removing a computer representation of one or more compounds complexed with a SAM domain; (b) (i) searching a data base for a compound with a similar geometric structure or similar chemical groups to the removed compounds using a computer program that searches computer representations of compounds from a database that have similar three dimensional structures and similar chemical groups, or (ii) replacing portions of the compounds complexed with the SAM domain with similar chemical structures (i.e. nearly identical shape and volume) from a database using a compound construction computer program that replaces computer representations of chemical groups with groups from a computer database, where the representations of the compounds are defined by structural coordinates.
- Potential modulators of SAM domains identified using the above-described methods may be prepared using methods described in standard reference sources utilized by those skilled in the art.
- organic compounds may be prepared by organic synthetic methods described in references such as March, 1994 Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, New York, McGraw Hill.
- Cellular assays, as well as animal model assays in vivo may be used to test the activity of a potential modulator of a SAM domain as well as diagnose a disease associated with inappropriate SAM domain activity. In vivo assays are also useful for testing the bioactivity of a potential modulator designed by the methods of the invention.
- the invention also relates to a potential modulator identified by the methods of the invention.
- the invention provides peptide molecules that modulate SAM domain function.
- the molecules are derived from the interface residues necessary for dimer formation.
- peptides of the invention include the amino acids Val 913, Val 914, Met 972, Met 976, Met 979, Val 944, and Leu 940 of the EphA4 SAM domain.
- proteins containing sequences corresponding to the sequences necessary for dimer formation of a SAM domain may be identified with a protein homology search, for example by searching available databases such as GenBank or SwissProt and various search algorithms and/or programs may be used including FASTA, BLAST (available as a part of the GCG sequence analysis package, University of Wisconsin, Madison, Wis.), or ENTREZ (National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD).
- specific peptides are contemplated that mediate SAM domain function comprising VVSV (SEQ ID. NO. 21), SAVVSV (SEQ ID. N0.22), FSAVV (SEQ ID. NO.23 ), FSAVVSV (SEQ ID. NO. 24), FSAVVSVGD (SEQ ID. NO. 25), VVSVGDWL (SEQ ID. NO. 26), FNTV (SEQ ID. NO. 27), FNTVDE (SEQ ID. NO. 28), FNTVDEWL (SEQ ID. NO. 29), TSFNTVDEWL (SEQ ID. NO. 30), TSFNTV (SEQ ID. NO. 31), YTSFNTV (SEQ ID. NO.
- RSEV SEQ ID. NO. 33
- RSEVLG SEQ ID. NO. 34
- RSEVLGWD SEQ ID. NO. 35
- VPFRSEV SEQ ID. NO. 36
- VPFRSEVLGW VPFRSEVLGW
- X and X r-6 represent 0 to 70, preferably 0 to 50 amino acids, more preferably 2 to 20 amino acids, and X 1 represents Leu, Phe, Asp, Ala, Glu, or Gly, preferably Leu or Gly, X 2 represents Glu, Asp, Ser, He, Ala, Arg, Lys, and Gin, preferably Glu or Asp, X 3 represents Ala, Val, Glu, Phe, Ser, He, Met, Leu, His, Gin, Arg, or Asp preferably Ala, Val, or Phe, X 4 is Val, Leu, Met, Phe, and He, preferably Val or Leu, or Phe, X 5 is Val, Ser, Leu, Asp, Ala, Pro, Asn, Lys, or Cys, preferably Val or Ser.
- a peptide of the formula I is provided: wherein X represents TT, ID, TS, DD, GYTT (SEQ ID. NO. 38), AAGYTT (SEQ ID. NO. 39), FTAAGYTT (SEQ ID. NO. 40), DNFTAAGYTT (SEQ ID. NO. 41), or YKDNFTAAGYTT (SEQ ID. NO. 42).
- X 6 represents HM, HMSQ (SEQ ID. NO. 43), HMSQD (SEQ ID. NO. 44), HMSQDD (SEQ ID. NO. 45), HMSQDDLA (SEQ ID. NO. 46), QMMM (SEQ ID. NO. 47), QMMMED (SEQ ID. NO.
- Preferred peptides of the formula I include the following: X-LEAVV-X 6 , X-FDVVS-X 6 , X-
- TSFDVVS (SEQ ID. NO. 77), TSFDVVSQ (SEQ ID. NO. 78), TSFDVVSQMM (SEQ ID. NO. 79), TSFDVVSQMMME (SEQ ID. NO. 80), TSFDVVSQMMMEDIL (SEQ ID. NO. 81), LEFLS (SEQ ID. NO. 82), LEFLSD (SEQ ID. NO. 83), LEFLSDIT (SEQ ID. NO. 84), LEFLSDITEE (SEQ ID. NO. 85), LEFLSDITEEDL (SEQ ID. NO. 86), DDLEFLS (SEQ ID. NO. 87), GWDDLEFLS (SEQ ID. NO. 88), DDLEFLSD (SEQ ID.
- X 7 and X 16 represent 0 to 70, preferably 0 to 50 amino acids, more preferably 2 to 20 amino acids, and X 8 represents Met, He, Ser, Leu, Asn, Phe, or Val, preferably Met, X 9 represents Arg, Ser, Lys, Met, Leu, Glu, Gin, or Asn, preferably Gin or Arg, X 10 represents Thr, Ala, Arg, Leu, Ser, Glu, Asp, Met, Lys, Gin, or Gly, preferably Thr, Ala, or Glu, X 11 represents Gin, Ser, Glu, Leu, Phe, Asp, Thr, Arg, preferably Gin or Arg, X 12 represents Met, Ala, He, Asn, Ser, Arg, Thr, Pro, Leu, Gin, Val, Lys, preferably Met or Arg, X 13 represents Gin, Asn, Pro, Ser, Tyr, Glu, Leu, Arg, or Lys, preferably Gin, Asn, or Arg, X 9
- a peptide of the formula II is provided: wherein X 7 represents QA, QV, NK, SVQA (SEQ ID. NO. 98), LSSVQA (SEQ ID. NO. 99), ILSSVQA (SEQ ID. NO. 100), NKILSSVQA (SEQ ID. NO. 101), HQNKILSSVQA (SEQ ID. NO. 102), THQNKILSSVQA (SEQ ID. NO. 103), ENIK (SEQ ID. NO. 104), SQEINK (SEQ ID. NO. 105), KLSQEINK (SEQ ID. NO. 106), ILNSIQV (SEQ ID. NO. 107), or NSIQV (SEQ ID. NO. NO.
- X 7 is HG, QS, HGRM (SEQ ID. NO. 109), HGRMVP (SEQ ID. NO. 110), QSVEV (SEQ ID. NO. 111), or TRKP (SEQ ID. NO. 112).
- Preferred peptides of the formula II include the following: X 7 -MRTQMQQM-X 16 , X 7 -
- MRTQMQQM (SEQ ID. NO. 113), QAMRTQMQQM (SEQ ID. NO. 1 14), SVQAMRTQMQQM (SEQ ID. NO. 115), LSSVQAMRTQMQQM (SEQ ID. NO. 116), ILSSVQAMRTQMQQM (SEQ ID. NO. 117), MRTQMQQMHG (SEQ ID. NO. 118), MRTQMQQMHGRM (SEQ ID. NO. 119), MRTQMQQMHGRMVPV (SEQ ID. NO. 120), NEERRSIF (SEQ ID. NO.
- INKNEERRSIF SEQ ID. NO. 122
- NEERRSIFTRKP SEQ ID. NO. 123
- MRAQMNQI SEQ ID. NO. 124
- MRAQMNQIQS SEQ ID. NO. 125
- MRAQMNQIQSVEV SEQ ID. NO. 126
- Truncated peptides may comprise peptides of about 7 to 10 amino acid residues
- the truncated peptides may have an amino group (-NH2), a hydrophobic group (for example, carbobenzoxyl, dansyl, or T-butyloxycarbonyl), an acetyl group, a 9-fluorenylmethoxy- carbonyl (PMOC) group, or a macromolecule including but not limited to lipid-fatty acid conjugates, polyethylene glycol, or carbohydrates at the amino terminal end.
- the truncated peptides may have a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecule including but not limited to lipid-fatty acid conjugates, polyethylene glycol, or carbohydrates at the carboxy terminal end.
- the peptides of the invention may also include analogs of a peptide of the invention and/or truncations of the peptide, which may include, but are not limited to a peptide of the invention containing one or more amino acid insertions, additions, or deletions, or both.
- Analogs of the peptide of the invention exhibit the activity characteristic of the peptide e.g. interference with SAM domain dimer formation, and may further possess additional advantageous features such as increased bioavailability, stability, or reduced host immune recognition.
- One or more amino acid insertions may be introduced into a peptide of the invention. Amino acid insertions may consist of a single amino acid residue or sequential amino acids.
- One or more amino acids may be added to the right or left termini of a peptide of the invention.
- Deletions may consist of the removal of one or more amino acids, or discrete portions from the peptide sequence.
- the deleted amino acids may or may not be contiguous.
- the lower limit length of the resulting analog with a deletion mutation is about 7 amino acids.
- the invention also includes a peptide conjugated with a selected protein, or a selectable marker (see below) to produce fusion proteins.
- the peptides of the invention may be prepared using recombinant DNA methods. Accordingly, nucleic acid molecules which encode a peptide of the invention may be incorporated in a known manner into an appropriate expression vector which ensures good expression of the peptide. Possible expression vectors include but are not limited to cosmids, plasmids, or modified viruses so long as the vector is compatible with the host cell used.
- the expression vectors contain a nucleic acid molecule encoding a peptide of the invention and the necessary regulatory sequences for the transcription and translation of the inserted protein-sequence. Suitable regulatory sequences may be obtained from a variety of sources, including bacterial, fungal, viral, mammalian, or insect genes.
- Suitable selectable marker genes are genes encoding proteins such as G418 and hygromycin which confer resistance to certain drugs, ⁇ - galactosidase, chloramphenicol acetyltransferase, firefly luciferase, or an immunoglobulin or portion thereof such as the Fc portion of an immunoglobulin preferably IgG.
- the selectable markers may be introduced on a separate vector from the nucleic acid of interest.
- the recombinant expression vectors may also contain genes that encode a fusion portion which provides increased expression of the recombinant peptide; increased solubility of the recombinant peptide; and or aid in the purification of the recombinant peptide by acting as a ligand in affinity purification.
- a proteolytic cleavage site may be inserted in the recombinant peptide to allow separation of the recombinant peptide from the fusion portion after purification of the fusion protein.
- fusion expression vectors examples include pGEX (Amrad Corp., Melbourne, Australia), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the recombinant protein.
- GST glutathione S-transferase
- Recombinant expression vectors may be introduced into host cells to produce a transformant host cell.
- Transformant host cells include prokaryotic and eukaryotic cells which have been transformed or transfected with a recombinant expression vector of the invention.
- the terms "transformed with”, “transfected with”, “transformation” and “transfection” are intended to include the introduction of nucleic acid (e.g. a vector) into a cell by one of many techniques known in the art.
- nucleic acid e.g. a vector
- prokaryotic cells can be transformed with nucleic acid by electroporation or calcium- chloride mediated transformation.
- Nucleic acid can be introduced into mammalian cells using conventional techniques such as calcium phosphate or calcium chloride co-precipitation, DEAE- dextran-mediated transfection, lipofectin, electroporation or microinjection. Suitable methods for transforming and transfecting host cells may be found in Sambrook et al. (Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press (1989)), and other laboratory textbooks.
- Suitable host cells include a wide variety of prokaryotic and eukaryotic host cells.
- the peptides of the invention may be expressed in bacterial cells such as E. coli, insect cells (using baculovirus), yeast cells or mammalian cells.
- Other suitable host cells can be found in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1991).
- the peptides of the invention may be tyrosine phosphorylated using the method described in Reedijk et al. (The EMBO Journal 11(4): 1365, 1992).
- tyrosine phosphorylation may be induced by infecting bacteria harbouring a plasmid containing a nucleotide sequence encoding a peptide of the invention, with a ⁇ gtl 1 bacteriophage encoding the cytoplasmic domain of the Elk tyrosine kinase as a LacZ-Elk fusion.
- Bacteria containing the plasmid and bacteriophage as a lysogen are isolated. Following induction of the lysogen, the expressed peptide becomes phosphorylated by the Elk tyrosine kinase.
- the peptides of the invention may be synthesized by conventional techniques.
- the peptides may be synthesized by chemical synthesis using solid phase peptide synthesis. These methods employ either solid or solution phase synthesis methods (see for example, J. M. Stewart, and J.D. Young, Solid Phase Peptide Synthesis, 2 nd Ed., Pierce Chemical Co., Rockford III. (1984) and G. Barany and R.B. Merrifield, The Peptides: Analysis Synthesis, Biology editors E. Gross and J. Meienhofer Vol. 2 Academic Press, New York, 1980, pp. 3-254 for solid phase synthesis techniques; and M Bodansky, Principles fo Peptide Synthesis, Springer- Verlag, Berlin 1984, and E. Gross and J.
- the peptides may be synthesized using 9-fluorenyl methoxycarbonyl (Fmoc) solid phase chemistry with direct incorporation of phosphotyrosine as the N- fluorenylmethoxy-carbonyl-O-dimethyl phosphono-L-tyrosine derivative.
- Fmoc 9-fluorenyl methoxycarbonyl
- N-terminal or C-terminal fusion proteins comprising a peptide of the invention conjugated with other molecules may be prepared by fusing, through recombinant techniques, the N-terminal or C-terminal of the peptide, and the sequence of a selected protein or selectable marker with a desired biological function.
- the resultant fusion proteins contain the peptide fused to the selected protein or marker protein as described herein.
- proteins which may be used to prepare fusion proteins include immunoglobulins, glutathione-S-transferase (GST), hemagglutinin (HA), and truncated myc. Cyclic derivatives of the peptides of the invention are also part of the present invention.
- Cyclization may allow the peptide to assume a more favorable conformation for association with molecules in complexes of the invention. Cyclization may be achieved using techniques known in the art. For example, disulfide bonds may be formed between two appropriately spaced components having free sulfhydryl groups, or an amide bond may be formed between an amino group of one component and a carboxyl group of another component. Cyclization may also be achieved using an azobenzene-containing amino acid as described by Ulysse, L., et al., J. Am. Chem. Soc. 1995, 117, 8466-8467. The side chains of Tyr and Asn may be linked to form cyclic peptides.
- the components that form the bonds may be side chains of amino acids, non-amino acid components or a combination of the two.
- cyclic peptides are contemplated that have a beta-turn in the right position. Beta-turns may be introduced into the peptides of the invention by adding the amino acids Pro-Gly at the right position.
- a more flexible peptide may be prepared by introducing cysteines at the right and left position of the peptide and forming a disulphide bridge between the two cysteines.
- the two cysteines are arranged so as not to deform the beta-sheet and turn.
- the peptide is more flexible as a result of the length of the disulfide linkage and the smaller number of hydrogen bonds in the beta-sheet portion.
- the relative flexibility of a cyclic peptide can be determined by molecular dynamics simulations.
- Peptide mimetics may be designed based on information obtained by systematic replacement of L-amino acids by D-amino acids, replacement of side chains with groups having different electronic properties, and by systematic replacement of peptide bonds with amide bond replacements. Local conformational constraints can also be introduced to determine conformational requirements for activity of a candidate peptide mimetic.
- the mimetics may include isosteric amide bonds, or D-amino acids to stabilize or promote reverse turn conformations and to help stabilize the molecule. Cyclic amino acid analogues may be used to constrain amino acid residues to particular conformational states.
- the mimetics can also include mimics of inhibitor peptide secondary structures. These structures can model the 3-dimensional orientation of amino acid residues into the known secondary conformations of the proteins.
- Peptoids may also be used which are oligomers of N-substituted amino acids and can be used as motifs for the generation of chemically diverse libraries of novel molecules.
- Peptides of the invention may be developed using a biological expression system. The use of these systems allows the production of large libraries of random peptide sequences and the screening of these libraries for peptide sequences that interact with particular amino acid residues. Libraries may be produced by cloning synthetic DNA that encodes random peptide sequences into appropriate expression vectors, (see Christian et al 1992, J. Mol. Biol. 227:711; Devlin et al, 1990 Science 249:404; Cwirla et al 1990, Proc. Natl. Acad, Sci. USA, 87:6378). Libraries may also be constructed by concurrent synthesis of overlapping peptides (see U.S. Pat. No. 4,708,871).
- Peptides of the invention may be used to identify lead compounds for drug development.
- the structure of the peptides described herein can be readily determined by a number of methods such as NMR and X-ray crystallography. A comparison of the structures of peptides similar in sequence, but differing in the biological activities they elicit in target molecules can provide information about the structure-activity relationship of the target. Information obtained from the examination of structure-activity relationships can be used to design either modified peptides, or other small molecules or lead compounds which can be tested for predicted properties as related to the target molecule. The activity of the lead compounds can be evaluated using assays similar to those described herein.
- Information about structure-activity relationships may also be obtained from co- crystallization studies. In these studies, a peptide with a desired activity is crystallized in association with a target molecule i.e. SAM domain, and the X-ray structure of the complex is determined. The structure can then be compared to the structure of the target molecule in its native state, and information from such a comparison may be used to design compounds expected to possess desired activities.
- a target molecule i.e. SAM domain
- the peptides of the invention may be converted into pharmaceutical salts by reacting with inorganic acids such as hydrochloric acid, sulfuric acid, hydrobromic acid, phosphoric acid, etc., or organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, succinic acid, malic acid, tartaric acid, citric acid, benzoic acid, salicylic acid, benezenesulfonic acid, and toluenesulfonic acids.
- inorganic acids such as hydrochloric acid, sulfuric acid, hydrobromic acid, phosphoric acid, etc.
- organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, succinic acid, malic acid, tartaric acid, citric acid, benzoic acid, salicylic acid, benezenesulfonic acid, and toluenesulf
- the peptides and antibodies specific for the peptides of the invention may be labelled using conventional methods with various enzymes, fluorescent materials, luminescent materials and radioactive materials. Suitable enzymes, fluorescent materials, luminescent materials, and radioactive material are well known to the skilled artisan.
- Antibodies and labeled antibodies specific for the peptides of the invention may be used to screen for proteins containing SAM domains.
- Computer modelling techniques known in the art may also be used to observe the interaction of a peptide of the invention, and truncations and analogs thereof with a SAM domain (for example, Homology Insight II and Discovery available from BioSym/Molecular Simulations, San Diego, California, U.S.A.). If computer modelling indicates a strong interaction, the peptide can be synthesized and tested for its ability to interfere with SAM domain dimer formation.
- a purified three dimensional SAM domain structure of the invention, the peptides of the invention, and the modulators identified using the methods of the invention may be used to modify the inappropriate activity of a SAM domain involved in a clinical disorder. They may be used in the treatment and diagnosis of disorders associated with aberrant T cell signaling and to modulate telomere function. In particular, they may be useful in methods for therapy of cellular senescence and immortalization controlled by telomere length and telomerase activity, and as selective immunosuppressants (e.g. in organ transplantation).
- cancers such as melanoma, ocular melanoma, leukemia, astrocytoma, glioblastoma, lymphoma, glioma, Hodgkin's lymphoma, multiple myeloma, sarcoma, myosarcoma, cholangiocarcinoma, squamous cell carcinoma, CLL, and cancers of the pancreas, breast, brain, prostate, bladder, thyroid, ovary, uterus, testis, kidney, stomach, colon and rectum, particularly leukemia including B-cell leukemia, T-cell leukemia, null-cell leukemia, myelogenous leukemia, and lymphocytic leukemia,
- the three dimensional SAM domain structure of the invention, the peptides of the invention, and the modulators identified using the methods of the invention may be used to modulate the biological activity of an Eph receptor or Eph ligand in a cell, including inhibiting or enhancing signal transduction activities of the receptor or ligand, and in particular modulating a pathway in a cell regulated by the ligand or receptor, particularly those pathways involved in neuronal development, axonal migration, pathfinding and regeneration.
- the three dimensional SAM domain structure of the invention, the peptides of the invention, and modulators identified using the methods of the invention will be useful as pharmaceuticals to modulate axonogenesis, nerve cell interactions and regeneration, to treat conditions such as neurodegenerative diseases and conditions involving trauma and injury to the nervous system, for example Alzheimer's disease, Parkinson's disease, Huntington's disease, demyelinating diseases, such as multiple sclerosis, amyotrophic lateral sclerosis, bacterial and viral infections of the nervous system, deficiency diseases, such as Wernicke's disease and nutritional polyneuropathy, progressive supranuclear palsy, Shy Drager's syndrome, multistem degeneration and olivo ponto cerebellar atrophy, peripheral nerve damage, and trauma and ischemia resulting from stroke.
- neurodegenerative diseases and conditions involving trauma and injury to the nervous system for example Alzheimer's disease, Parkinson's disease, Huntington's disease, demyelinating diseases, such as multiple sclerosis, amyotrophic lateral
- the present invention thus provides a method for treating cancer (e.g. leukemia), and disorders associated with T cell signaling, modulating telomere function, or affecting neuronal development or regeneration, in a subject comprising administering to a subject an effective amount of a three dimensional SAM domain structure of the invention, a peptide of the invention, or a modulator identified using the methods of the invention.
- cancer e.g. leukemia
- the invention also contemplates a method for stimulating or inhibiting axonogenesis in a subject comprising administering to a subject an effective amount of a three dimensional SAM domain structure of the invention, a peptide of the invention, or a modulator identified using the methods of the invention.
- the invention still further relates to a pharmaceutical composition which comprises a purified three dimensional SAM domain structure of the invention, a peptide of the invention, or a modulator identified using the methods of the invention, and a pharmaceutically acceptable carrier, diluent or excipient.
- the pharmaceutical compositions may be used to stimulate or inhibit neuronal development, regeneration and axonal migration associated with neurodegenerative conditions, and conditions involving trauma and injury to the nervous system. They may also be used to treat cancer and disorders associated with T cell signaling, and modulate telomere function.
- the compositions of the invention are administered to subjects in a biologically compatible form suitable for pharmaceutical administration in vivo.
- biologically compatible form suitable for administration in vivo is meant a form of the protein to be administered in which any toxic effects are outweighed by the therapeutic effects of the protein.
- subject is intended to include mammals and includes humans, dogs, cats, mice, rats, and transgenic species thereof.
- Administration of a therapeutically active amount of the pharmaceutical compositions of the present invention is defined as an amount effective, at dosages and for periods of time necessary to achieve the desired result.
- a therapeutically active amount of a three dimensional SAM domain structure of the invention, peptides of the invention, or modulators of the invention may vary according to factors such as the condition, age, sex, and weight of the individual. Dosage regimes may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.
- the active compound may be administered in a convenient manner such as by injection (subcutaneous, intravenous, etc.), oral administration, inhalation, transdermal application, or intracerebral administration.
- pharmaceutical compositions of the invention are administered directly to the peripheral or central nervous system, for example by administration intracerebrally.
- a pharmaceutical composition of the invention can be administered to a subject in an appropriate carrier or diluent, co-administered with enzyme inhibitors or in an appropriate carrier such as microporous or solid beads or liposomes.
- pharmaceutically acceptable carrier as used herein is intended to include diluents such as saline and aqueous buffer solutions.
- Liposomes include water-in-oil-in-water emulsions as well as conventional liposomes (Strejan et al., (1984) J. Neuroimmunol 7:27).
- the active compound may also be administered parenterally or intraperitoneally.
- Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils.
- these preparations may contain a preservative to prevent the growth of microorganisms.
- the active compound may be coated to protect the compound from the action of enzymes, acids and other natural conditions which may inactivate the compound.
- the pharmaceutical compositions may be administered locally to stimulate axonogenesis and pathfinding, for example the compositions may be administered in areas of local nerve injury or in areas where normal nerve pathway development has not occurred.
- the pharmaceutical compositions may also be placed in a specific orientation or alignment along a presumptive pathway to stimulate axon pathfinding along that line, for example the pharmaceutical compositions may be incorporated on microcarriers laid down along the pathway.
- the pharmaceutical compositions of the invention may be used to stimulate formation of connections between areas of the brain, such as between the two hemispheres or between the thalamus and ventral midbrain.
- the pharmaceutical compositions may be used to stimulate formation of the medial tract of the anterior commissure or the habenular interpeduncle.
- a nucleic acid including a promoter operatively linked to a heterologous polypeptide may be used to produce high-level expression of the polypeptide in cells transfected with the nucleic acid.
- DNA or isolated nucleic acids may be introduced into cells of a subject by conventional nucleic acid delivery systems. Suitable delivery systems include liposomes, naked DNA, and receptor-mediated delivery systems, and viral vectors such as retroviruses, herpes viruses, and adenoviruses.
- EXAMPLE The following methods were used to determine the crystal structure of the SAM domain of the Eph receptor isoform A4.
- Protein expression, mutagenesis and purification The SAM domain of the Eph receptor isoform A4 (residues 890 to 981) was expressed in E. coli as a GST fusion protein using the pGEX-2T vector (Pharmacia).
- the Quickchange kit (Stratagene) was used to generate site directed mutants for dimerization analysis and for heavy atom phasing. Protein was purified by affinity chromatography using glutathione Sepharose beads (Pharmacia). Bound protein was eluted by cleavage with thrombin. After concentrating to 10 mM, protein was applied to a Superdex 75 gel filtration column (Pharmacia) for final purification and characterization.
- the solution dimer corresponds to a crystallographic dimer generated from the asymetric unit by a two fold rotation parallel to the unique crystal axis.
- Crystals were cryo-protected in reservoir buffer emiched to 20% (w/v) PEG 8000 and 20% (v/v) ethylene glycol prior to stream freezing.
- Heavy atom derivatives were prepared by soaking crystals overnight in 1-10 mM heavy atom solution prepared in cryo-protection buffer.
- Native and derivative diffraction data were collected on frozen crystals (108°K) using a Marr 345 imaging plate detector system with an RU200 rotating anode generator (Table 1). Data processing and reduction was carried out with the HKL, DENZO, and SCALEPACK programs.
- Single isomorphous replacement (SIR) protein phases were calculated using lead derivative data collected on two separate protein crystals.
- the heavy atom site was identified by the Patterson search program HASSP [Terwilliger, 1987].
- a Glu 941 to Cys site directed mutant of the EphA4 SAM domain construct was employed for mercury derivatization.
- the heavy atom position of the mercury derivative data which was collected on three separate crystals, was identified by difference Fourier synthesis.
- Multiple isomorphous replacement and anomalous scattering (MIRAS) phases using only the lead derivative anomalous signal, were calculated and iterative rounds of automatic solvent boundary determination/density modification were performed using the PHASES package [Furey, 1990].
- the resultant experimental electron density map allowed for the complete tracing of the SAM domain backbone structure.
- Model building was performed using O [Jones, 1991]. A starting model comprising approximately 65% of the total structure was refined using XPLOR [Brunger, 1992]. Bulk solvent correction was applied during refinement and simulated annealing protocols were employed. The remaining structure was built into 2F 0 -F C electron density maps generated with XPLOR. The final refinement statistics are shown in Table 1. The first 20 residues of the SAM domain construct are disordered (residues 890 to 909) and have not been modeled. No amino acid residues occupy disallowed regions of the Ramachandran plot and 94 % occupy the most favored regions. Results:
- the X-ray crystal structure of the SAM domain from the EphA4 receptor tyrosine kinase was determined. The boundaries of the structure were defined by limited proteolysis and mass-spectrometry. Overall, the structure of the homodimer is oblong and arises from the association of two 'lobster claw' shaped subunits. Each subunit possesses a globular fold consisting of an N-terminal extended strand segment, followed by four short ⁇ helices ( ⁇ l to ⁇ 4) and one long C-terminal helix ⁇ 5 ( Figure 2A, 2B, and 2C).
- N- and the C-termini are located on one side of the subunit fold, similar to other protein interaction modules with signaling function (SH3, SH2, PH domains etc.) [Kuriyan, 1997]. However, in contrast to these other domains, the termini compose the functional end of the molecule rather than lying opposite to the ligand-binding surface.
- the N-terminal strand region and the C-terminal helix ⁇ 5 extend from the subunit core and interdigitate in a pincer like manner with the termini of a second subunit, to form an elaborate dimer interface.
- ⁇ -helices ⁇ l and ⁇ 3 contribute side chains to the dimer interface.
- the N-terminal strands cross in an anti-parallel manner and project the side chains of Ala 912, Val 913, Val 914 and Phe 910 downward to form one mandible of the 'lobster claw' shaped subunit.
- the C-terminal helices ⁇ 5 also cross in an anti-parallel manner with each ⁇ -helix projecting the side chains of Met 972, Met 976, and Met 979, upwards to form the second mandible. Together these side chains compose a hydrophobic core that is fully continuous with those of the individual subunits.
- Residues bridging the subunit and interface cores include Tip 919, Ala 922 and He 923 from helix ⁇ l and Leu 940 and Val 944 from helix ⁇ 3.
- the conserved side chain of arginine 973 forms intermolecular electrostatic interactions with the free carboxylate of glycine 981 and a stabilizing charge/helix dipole interaction with the C-terminus of helix ⁇ 5 ( Figure 2C).
- Additional polar residues located at or in close proximity to the dimer interface include His 980, Gin 975, His 945, Gin 977, Glu 941 and Ser 911.
- the crystallographic model for SAM domain dimerization is attractive for a number of reasons. Firstly, in the case of the Eph receptors, the linkers between the SAM and the catalytic domains is short (5 residues of poorly conserved sequence) so that the N-termini of the dimer would have to be oriented in the same direction and in close proximity if the kinase domains of clustered receptors were to be juxtaposed. The structure shows this to be the case. Secondly, the mechanism of dimerization revealed by the structure could account for the observation that the SAM domain is found at either terminus of signaling proteins.
- the SAM domain differs from modules such as SH2 and SH3 domains, which can readily be located at internal positions in a polypeptide chain since the ligand-binding site is located opposite to the location of the N- and C-termini [Kuriyan, 1997].
- SAM dimerization may contribute to receptor oligomerization and activation by bringing catalytic elements into proximity for autophosphorylation.
- the SAM domain may have a direct inhibitory interaction with the kinase domain that can be competed away by dimerization.
- SAM domain mediated dimerization might maintain opposing catalytic domains in a mutually inaccessible, and thus repressed state.
- the Eph SAM domains might also recruit signaling partners through heteromeric SAM-SAM interactions, or through specific recognition of cytoplasmic proteins by the Eph SAM dimer.
- SAM dimerization might be constitutive, but controlled through co-operative or antagonistic interactions with other clustering forces. Dimerization could potentially be controlled by modifications such as tyrosine phosphorylation, and indeed a residue within the SAM domain of the EphBl receptor can become tyrosine phosphorylated in vivo [Stein, 1996]. Finally, the five residues that lie C-terminal to the Eph SAM domain represent a potential binding site for PDZ domain proteins[Hock, 1998],which might influence the organization of the SAM domain.
- EphA4 domain reveals a novel mechanism through which modular domains control protein-protein interactions. Since SAM domains are found in cell surface receptors, cytoplasmic signaling proteins, and transcriptional activators and repressors, as well as chimeric human oncoproteins, these results have general implications for understanding the formation of complexes involved in normal and oncogenic signal transduction.
- FIG 1A shows a sequence alignment of SAM domains from selected proteins. Secondary structure is indicated for the SAM domain from the EphA4 receptor tyrosine kinase. Residue numbers for the start of each SAM domain are shown on the left and Genebank accession numbers on the right. conserveed hydrophobic residues are colored green, acidic residues red, basic residues blue, polar residues orange and glycines are colored pink. Residues at the dimer interface shown in Figure 2C are indicated (•). Liprin ⁇ l contains 3 SAM domains designated SI, S2 and S3.
- Figure IB shows a selection of multi-domain proteins containing SAM domain (S) is shown.
- Domains listed include, tyrosine or serine/threonine kinase catalytic domains, myosin-like domain, F- actin binding domain (F-actin BD), PDZ domain, SH2 domain, inositol phosphatase catalytic domain
- TM transmembrane region
- Figure 2A, 2B, and 2C Ribbons depiction of the SAM homo-dimer viewed ( Figure 2A) down the twofold symmetry axis and ( Figure 2B) perpendicular to the symmetry axis.
- the dimer subunits are coloured red and blue and ⁇ -helices are labeled.
- Figure 2C Ribbons stereo view highlighting the dimer interface region.
- Aromatic, aliphatic, methionine, histidine and arginine interacting side chains are coloured light blue, green, yellow, orange, and blue (see Figure 1A for residue identification). All ribbon diagrams were generated using RIBBONS [Carson, 1991].
- Figure 3A, B Molecular surface and worm representations of the SAM homodimer.
- the molecular surface of one subunit is shown with hydrophobic (Met, Val, Leu, He, Phe,), basic (Arg, Lys) and acidic (Glu, Asp) side chains coloured green, blue and red, respectively.
- the two perspectives differ by a 90° rotation about the vertical axis.
- Figure 3B the twofold rotation axis relating the two subunits of the dimer is shown.
- the buried surface area of the dimer interface is 1923 A. All molecular surfaces were generated using GRASP [Nicholls, 1991].
- Figure 4. Gel filtration elution profile of wild type and single or double site mutants of the
- Chromatograms correspond to the loading of equivalent concentrations (10 mM) and total volumes (100 ⁇ l) of protein on a Superdex-75 gel filtration column (24 ml bed volume). The column was calibrated using Pharmacia low molecular weight standards.
- ⁇ Phasing Power is RMS (
- ATOM 12 N PHE 910 30 .779 31 .717 12 .369 1, .00 37, .87
- ATOM 102 CA GLN 921 9. ,447 25. ,848 18. 538 1. 00 16. ,28
- ATOM 120 CA ILE 923 6 .239 26 .400 14 .153 1 .00 16 .57
- ATOM 157 O ASP 926 10. .315 19. .229 19. .987 1. .00 17. .30
- ATOM 163 CD ARG 927 4. ,780 16. ,271 18. .058 1. ,00 15. ,27
- ATOM 166 CZ ARG 927 2. .557 17. .356 18. ,111 1. ,00 18. ,27
- ATOM 180 CD1 TYR 928 7 .501 16 .774 14 .659 1, .00 10 .58
- ATOM 191 CA LYS 929 13, .633 18, .208 18, .031 1, .00 17, .93
- ATOM 205 CB ASP 930 14. .958 13, .932 19. .836 1. .00 23. .30
- ATOM 209 C ASP 930 15. .390 14. .144 17. .374 1. .00 17. .86
- ATOM 213 CA ASN 931 14. .200 13. .504 15. .335 1. .00 13. .52
- ATOM 217 ND2 ASN 931 11. ,531 13. .386 16. .810 1. .00 10. .00
- ATOM 218 HD21 ASN 931 12. .030 14. .158 17. .132 1. .00 0. .00
- ATOM 219 HD22 ASN 931 10. .842 12. .912 17. .313 1. ,00 0. .00
- ATOM 220 C ASN 931 15. .220 14. .106 14. ,363 1. ,00 14. .47
- ATOM 236 CA THR 933 19 .293 15 .878 15 .779 1 .00 19 .46
- ATOM 245 CA ALA 934 19 .504 12 .073 15 .722 1 .00 17 .60
- ATOM 251 CA ALA 935 19, .645 12 .144 11, .920 1, .00 14, .43
- ATOM 262 CA TYR 937 20. .034 17. .705 10. .883 1. .00 17. .59
- ATOM 276 CA THR 938 21. ,668 20. .182 13. .230 1. .00 20. .43
- ATOM 306 CD GLU 941 24 .371 26 .712 6 .317 1 .00 45. .17
- ATOM 313 CA ALA 942 20, .531 20 .998 6, .080 1, .00 19, .22
- ATOM 335 CA HIS 945 17. .148 20. .776 1. .638 1. .00 24. .47
- ATOM 336 CB HIS 945 18. 627 20. .625 1. ,270 1. 00 29. .45
- ATOM 340 HD1 HIS 945 17. 684 22. .691 -0. ,399 1. .00 10. .00
- ATOM 368 CD GLN 948 5. .542 13 .007 1 .323 1, .00 31 .25
- ATOM 396 CB LEU 951 9. .802 14. .722 6. ,815 1. ,00 11. .55
- ATOM 398 CD1 LEU 951 9. ,085 17. .016 6. ,102 1. ,00 11. .51
- ATOM 403 H ALA 952 9. ,920 11. ,800 5. ,686 1. 00 10. ,00
- ATOM 404 CA ALA 952 9. ,341 10. ,229 6. 991 1. 00 11. ,84
- ATOM 410 CA ARG 953 12 .776 8 .591 7 .390 1 .00 15 .00
- ATOM 427 CA ILE 954 13 .303 10 .891 10, .396 1. .00 15, .90
- ATOM 431 CD1 ILE 954 15, .609 11, .919 8, .863 1. .00 23. .36
- ATOM 441 CA ILE 956 7, .710 12. .441 11. .055 1. .00 15. .41
- ATOM 445 CD1 ILE 956 9, .793 15. .712 11. .340 1. ,00 14. .38
- ATOM 450 CA THR 957 5. .031 10. .231 9. .506 1. ,00 17. .30
- ATOM 459 CA ALA 958 1. .982 12. .406 10. ,223 1. 00 15. ,66
- ATOM 465 CA ILE 959 1. ,286 14. ,017 6. 838 1. 00 16. ,17
- ATOM 482 H HIS 961 1 .713 16 .175 10 .007 1 .00 10 .00
- ATOM 484 CB HIS 961 3, .689 16, .789 11 .532 1. .00 15, .19
- ATOM 488 HD1 HIS 961 3, .301 15, .070 13 .827 1. .00 10, .00
- ATOM 507 H ASN 963 2. .932 17. .852 6. .489 1. .00 10. .00
- ATOM 508 CA ASN 963 3. .232 19. .649 5. .415 1. ,00 16. ,00
- ATOM 509 CB ASN 963 1. . 161 19. ,562 4. .981 1. ,00 16. ,74
- ATOM 513 HD21 ASN 963 0. ,085 17. .835 4. .647 1. 00 0. 00
- ATOM 514 HD22 ASN 963 0. ,384 17. .209 3. .108 1. ,00 0. ,00
- ATOM 558 CA SER 968 7. .789 26. .459 6, .570 1. .00 17. .49
- ATOM 563 O SER 968 9. .661 27. .654 5. .650 1. ,00 18. .78
- ATOM 566 CA VAL 969 10. .863 25. .362 4. .598 1. ,00 16. .32
- ATOM 580 HE21 GLN 970 5. ,590 25. ,769 1. .273 1. 00 10. ,00
- ATOM 601 CA ARG 973 13, .803 29 .690 1 .382 1, .00 22, .73
- ATOM 604 CD ARG 973 13, .681 26 .058 0 .056 1, .00 19. .57
- ATOM 614 C ARG 973 13. .507 31, .010 0, .670 1. .00 24. .33
- ATOM 618 CA THR 974 11. .795 32. .576 -0. .113 1. .00 31. ,31
- ATOM 619 CB THR 974 10. .264 32, .669 -0. .193 1. .00 30. .78
- ATOM 627 CA GLN 975 12. .858 34. .715 2. .869 1. .00 42. .57
- ATOM 630 CD GLN 975 12. .891 35. .080 6. .751 1. ,00 54. ,33
- ATOM 648 CA GLN 977 16 .235 34 .859 -1 .472 1 .00 45 .08
- ATOM 670 N MET 979 17. .361 37. .949 1, .070 1. .00 49. .20
- ATOM 673 CB MET 979 18. .939 37. .138 2. .767 1. .00 50. .98
- ATOM 678 O MET 979 20. .842 38. .788 1. .392 1. .00 48. ,62
- ATOM 680 H HIS 980 18. .519 38. .655 -0. .702 1. .00 10. .00
- ATOM 681 CA HIS 980 20. .454 39. .155 -1. .319 1. ,00 44. .17
- ATOM 686 HD1 HIS 980 20. ,768 37. .181 -4. .053 1. ,00 10. ,00
- ATOM 694 CA GLY 981 18. 623 41. .249 -3. .900 1. 00 46. 12
- Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses Genes Dev 12, 667-78 (1998).
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002355163A CA2355163A1 (en) | 1998-12-18 | 1999-12-17 | Three dimensional structure of a sterile alpha motif domain |
EP99960741A EP1141016A1 (en) | 1998-12-18 | 1999-12-17 | Three dimensional structure of a sterile alpha motif domain |
AU17642/00A AU1764200A (en) | 1998-12-18 | 1999-12-17 | Three dimensional structure of a sterile alpha motif domain |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11292998P | 1998-12-18 | 1998-12-18 | |
US60/112,929 | 1998-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000037500A1 true WO2000037500A1 (en) | 2000-06-29 |
Family
ID=22346604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA1999/001209 WO2000037500A1 (en) | 1998-12-18 | 1999-12-17 | Three dimensional structure of a sterile alpha motif domain |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1141016A1 (en) |
AU (1) | AU1764200A (en) |
CA (1) | CA2355163A1 (en) |
WO (1) | WO2000037500A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004028551A1 (en) * | 2002-09-24 | 2004-04-08 | The Burnham Institute | Novel agents that modulate eph receptor activity |
US6927203B1 (en) | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
US7192698B1 (en) | 1999-08-17 | 2007-03-20 | Purdue Research Foundation | EphA2 as a diagnostic target for metastatic cancer |
EP1852441A3 (en) * | 2002-09-24 | 2008-02-13 | The Burnham Institute | Agents that modulate EPH receptor activity |
US7402298B1 (en) | 2000-09-12 | 2008-07-22 | Purdue Research Foundation | EphA2 monoclonal antibodies and methods of making and using same |
US7582438B2 (en) | 2005-01-27 | 2009-09-01 | Burnham Institute For Medical Research | EphB receptor-binding peptides |
CN109637596A (en) * | 2018-12-18 | 2019-04-16 | 广州市爱菩新医药科技有限公司 | A kind of drug target prediction technique |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993010816A1 (en) * | 1991-12-02 | 1993-06-10 | Board Of Regents, The University Of Texas System | Compositions for eliciting cytotoxic t-lymphocyte responses against viruses |
WO1995027060A2 (en) * | 1994-04-04 | 1995-10-12 | Regeneron Pharma | Biologically active eph family ligands |
WO1996040189A1 (en) * | 1995-06-07 | 1996-12-19 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
WO1997014966A1 (en) * | 1995-10-13 | 1997-04-24 | Mount Sinai Hospital Corporation | Method of activating a novel ligand regulatory pathway |
WO1998047088A1 (en) * | 1997-04-15 | 1998-10-22 | Universite De Montreal | Energetically favorable binding site determination between two molecules |
-
1999
- 1999-12-17 AU AU17642/00A patent/AU1764200A/en not_active Abandoned
- 1999-12-17 EP EP99960741A patent/EP1141016A1/en not_active Withdrawn
- 1999-12-17 WO PCT/CA1999/001209 patent/WO2000037500A1/en not_active Application Discontinuation
- 1999-12-17 CA CA002355163A patent/CA2355163A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993010816A1 (en) * | 1991-12-02 | 1993-06-10 | Board Of Regents, The University Of Texas System | Compositions for eliciting cytotoxic t-lymphocyte responses against viruses |
WO1995027060A2 (en) * | 1994-04-04 | 1995-10-12 | Regeneron Pharma | Biologically active eph family ligands |
WO1996040189A1 (en) * | 1995-06-07 | 1996-12-19 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
WO1997014966A1 (en) * | 1995-10-13 | 1997-04-24 | Mount Sinai Hospital Corporation | Method of activating a novel ligand regulatory pathway |
WO1998047088A1 (en) * | 1997-04-15 | 1998-10-22 | Universite De Montreal | Energetically favorable binding site determination between two molecules |
Non-Patent Citations (5)
Title |
---|
HIMANEN JUHA-PEKKA ET AL: "Crystal structure of the ligand-binding domain of the receptor tyrosine kinase EphB2.", NATURE (LONDON) DEC. 3, 1998, vol. 396, no. 6710, 3 December 1998 (1998-12-03), pages 486 - 491, XP002134939, ISSN: 0028-0836 * |
LYBRAND T P: "LIGAND-PROTEIN DOCKING AND RATIONAL DRUG DESIGN", CURRENT OPINION IN STRUCTURAL BIOLOGY,GB,CURRENT BIOLOGY LTD., LONDON, vol. 5, 1 January 1995 (1995-01-01), pages 224 - 228, XP000764926, ISSN: 0959-440X * |
SCHULTZ JOERG ET AL: "SAM as a protein interaction domain involved in developmental regulation.", PROTEIN SCIENCE 1997, vol. 6, no. 1, 1997, pages 249 - 253, XP002134938, ISSN: 0961-8368 * |
STAPLETON DAVID ET AL: "The crystal structure of an Eph receptor SAM domain reveals a mechanism for modular dimerization.", NATURE STRUCTURAL BIOLOGY JAN., 1999, vol. 6, no. 1, January 1999 (1999-01-01), pages 44 - 49, XP002134936, ISSN: 1072-8368 * |
THANOS CHRISTOPHER D ET AL: "Oligomeric structure of the human EphB2 receptor SAM domain.", SCIENCE (WASHINGTON D C) FEB. 5, 1999, vol. 283, no. 5403, 5 February 1999 (1999-02-05), pages 833 - 836, XP002134937, ISSN: 0036-8075 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6927203B1 (en) | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
US8591887B2 (en) | 1999-08-17 | 2013-11-26 | Purdue Research Foundation | EPHA2 as a therapeutic target for cancer |
US7192698B1 (en) | 1999-08-17 | 2007-03-20 | Purdue Research Foundation | EphA2 as a diagnostic target for metastatic cancer |
US7776327B2 (en) | 1999-08-17 | 2010-08-17 | Purdue Research Foundation | EphA2 as a therapeutic target for cancer |
US7402298B1 (en) | 2000-09-12 | 2008-07-22 | Purdue Research Foundation | EphA2 monoclonal antibodies and methods of making and using same |
US8461119B2 (en) | 2002-09-24 | 2013-06-11 | The Burnham Institute | Agents that modulate Eph receptor activity |
EP1852441A3 (en) * | 2002-09-24 | 2008-02-13 | The Burnham Institute | Agents that modulate EPH receptor activity |
WO2004028551A1 (en) * | 2002-09-24 | 2004-04-08 | The Burnham Institute | Novel agents that modulate eph receptor activity |
JP2006507256A (en) * | 2002-09-24 | 2006-03-02 | ザ バーナム インスティチュート | Novel drug that modulates Eph receptor activity |
US7582438B2 (en) | 2005-01-27 | 2009-09-01 | Burnham Institute For Medical Research | EphB receptor-binding peptides |
US7999069B2 (en) | 2005-01-27 | 2011-08-16 | Sanford-Burnham Medical Research Institute | EphB receptor-binding peptides |
CN109637596A (en) * | 2018-12-18 | 2019-04-16 | 广州市爱菩新医药科技有限公司 | A kind of drug target prediction technique |
CN109637596B (en) * | 2018-12-18 | 2023-05-16 | 广州市爱菩新医药科技有限公司 | Drug target prediction method |
Also Published As
Publication number | Publication date |
---|---|
AU1764200A (en) | 2000-07-12 |
CA2355163A1 (en) | 2000-06-29 |
EP1141016A1 (en) | 2001-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fütterer et al. | Structural basis for Syk tyrosine kinase ubiquity in signal transduction pathways revealed by the crystal structure of its regulatory SH2 domains bound to a dually phosphorylated ITAM peptide | |
Rittinger et al. | Structural analysis of 14-3-3 phosphopeptide complexes identifies a dual role for the nuclear export signal of 14-3-3 in ligand binding | |
Huxford et al. | The crystal structure of the IκBα/NF-κB complex reveals mechanisms of NF-κB inactivation | |
Karpusas et al. | Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes | |
US7825089B2 (en) | Three-dimensional structures of TALL-1 and its cognate receptors and modified proteins and methods related thereto | |
US20070274918A1 (en) | LINGO-1 structure | |
van Agthoven et al. | Structural characterization of the stem–stem dimerization interface between prolactin receptor chains complexed with the natural hormone | |
AU1254700A (en) | Peptides that modulate the interaction of b class ephrins and pdz domains | |
Li et al. | Structurally distinct recognition motifs in lymphotoxin-β receptor and CD40 for tumor necrosis factor receptor-associated factor (TRAF)-mediated signaling | |
Zhang et al. | The substrate binding domains of human SIAH E3 ubiquitin ligases are now crystal clear | |
US6682921B1 (en) | Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases | |
WO2000037500A1 (en) | Three dimensional structure of a sterile alpha motif domain | |
WO2003023012A2 (en) | Crystal structure of interleukin-22 and uses thereof | |
Ha et al. | Structure of the ABL2/ARG kinase in complex with dasatinib | |
CA2459890A1 (en) | Crystal structure of baff, and use thereof in drug design | |
US20040197893A1 (en) | HDM2-inhibitor complexes and uses thereof | |
EP1358211A2 (en) | Methods for regulating the kinase domain of ephb2 | |
EP0833847B1 (en) | Crystals of fragments of cd40 ligand and their use | |
US7584087B2 (en) | Structure of protein kinase C theta | |
Batra-Safferling et al. | Structural studies of the phosphatidylinositol 3-kinase (PI3K) SH3 domain in complex with a peptide ligand: role of the anchor residue in ligand binding | |
US20050079503A1 (en) | Binding domain of Siah (seven in absentia homolog) protein | |
US20050085626A1 (en) | Polo domain structure | |
Fujino et al. | Structural analysis of an MK2–inhibitor complex: insight into the regulation of the secondary structure of the Gly-rich loop by TEI-I01800 | |
US20060234293A1 (en) | Polypeptide methods and means | |
EP4367226A1 (en) | Crystal structures of alk and ltk receptor tyrosine kinases and their ligands |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2000 17642 Country of ref document: AU Kind code of ref document: A |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2355163 Country of ref document: CA Kind code of ref document: A Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09883859 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999960741 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999960741 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999960741 Country of ref document: EP |